Ignite Creation Date:
2025-12-25 @ 2:54 AM
Ignite Modification Date:
2025-12-30 @ 12:46 PM
Study NCT ID:
NCT01292733
Status:
TERMINATED
Last Update Posted:
2016-01-20
First Post:
2010-11-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
Sponsor:
Swedish Medical Center
Organization:
Study Overview
Official Title:
Ovarian Cancer Early Detection Screening Program
Status:
TERMINATED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Closed per local IRB due to advancements in standard ovarian cancer screening.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OCEDP
Brief Summary:
The main purpose of this program is to see whether periodically measuring CA-125 (tumor marker) levels in the blood and undergoing transvaginal ultrasounds over time will be effective in the early detection of ovarian cancer.
Detailed Description:
The program will offer twice yearly CA-125 blood tests and annual transvaginal ultrasounds to monitor women at high risk for ovarian cancer. In addition to the main purpose of providing ovarian cancer screening, the researchers would also like to build a repository of blood specimens for use in ovarian and breast cancer research and to offer genetics counseling sessions to help educate women about risk-reducing options.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| CRC 08108 | OTHER | Swedish Medical Center | View |